Prognostic value of STC 1 expression in ovarian cancer

Objective: The goal of this study was to explore the prognostic role of STC1 in patients with ovarian cancer (OC). Methods: A retrospective study was performed. In total, there were 136 OC patients undergoing surgical treatment in Renmin Hospital of Wuhan University during January 2013 to September 2016. The tissue expression of STC1 was measured by immunohistochemistry staining. Serum level of STC1 and CA125 were tested by ELISA kits. Results: STC1 expression was elevated in OC patients compared with non-OC patients and it correlated with OC patients’ clinical characteristics and overall survival. Additionally, higher serum STC1 level was positively correlated with CA125 and both serum STC1 and CA125 were independent prognostic markers in OC. Furthermore, the combination of STC1 and CA125 showed better predictive power than the two indicators operated alone. Conclusion: Therefore, STC1 acted as an oncogene in OC development and progression. Detection of either STC1 expression in tissue or serum could be a useful prognosis marker.